Alvogen has been denied an attempt to challenge a US patent protecting Celgene’s Revlimid (lenalidomide) via the inter partes review (IPR) process.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?